<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Little is known about the biological characteristics that determine the prognosis of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In previous work we reported three different histological patterns of the <z:e sem="disease" ids="C0023903" disease_type="Neoplastic Process" abbrv="">tumour-liver</z:e> interface of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e>, termed the pushing, replacement and <z:e sem="disease" ids="C1511789" disease_type="Disease or Syndrome" abbrv="">desmoplastic</z:e> growth pattern (GP) </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this study was to confirm differences in angiogenic and hypoxic properties of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> with different GPs in a large data set and to study the value of the GP as a prognostic factor </plain></SENT>
<SENT sid="3" pm="."><plain>In 205 patients undergoing a resection of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e>, the GP of the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> was determined using <z:chebi fb="1" ids="51686">haematoxylin</z:chebi>-eosin and Gordon Sweet's silver staining </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cell proliferation fraction (TCP%), endothelial cell proliferation fraction (ECP%) and carbonic anhydrase 9 (CA9) expression were determined using immunohistochemistry </plain></SENT>
<SENT sid="5" pm="."><plain>Standard clinicopathological data and overall survival were recorded </plain></SENT>
<SENT sid="6" pm="."><plain>27.8, 15.6, 34.6 and 17.6 % of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> had a replacement, pushing, <z:e sem="disease" ids="C1511789" disease_type="Disease or Syndrome" abbrv="">desmoplastic</z:e> and mixed GP, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Analyses of TCP%, ECP% and CA9 expression demonstrated that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> with a replacement GP are non-angiogenic, while the ones with a pushing GP are the most angiogenic with <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> being, at least partially, <z:mp ids='MP_0005039'>hypoxia</z:mp>-driven </plain></SENT>
<SENT sid="8" pm="."><plain>GP (pushing or not) was the only independent predictor of survival at 2 years </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> grow according to different GP patterns with different angiogenic properties </plain></SENT>
<SENT sid="10" pm="."><plain>At 2 years of follow-up a GP with a pushing component was an independent predictor of poor survival, suggesting that the pushing GP is characterized by a more aggressive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> biology </plain></SENT>
<SENT sid="11" pm="."><plain>Further elucidation of the mechanisms and biological pathways involved in and responsible for the differences in GP between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> in different patients might lead to therapeutic agents and strategies taking advantage of this 2 year 'window of opportunity' </plain></SENT>
</text></document>